JPWO2020084161A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020084161A5 JPWO2020084161A5 JP2021522958A JP2021522958A JPWO2020084161A5 JP WO2020084161 A5 JPWO2020084161 A5 JP WO2020084161A5 JP 2021522958 A JP2021522958 A JP 2021522958A JP 2021522958 A JP2021522958 A JP 2021522958A JP WO2020084161 A5 JPWO2020084161 A5 JP WO2020084161A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- promoter
- sequence
- factor
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 35
- 108020004707 nucleic acids Proteins 0.000 claims 33
- 210000004185 Liver Anatomy 0.000 claims 12
- 108010023321 Factor VII Proteins 0.000 claims 8
- 102100009906 F7 Human genes 0.000 claims 7
- 229940012413 factor VII Drugs 0.000 claims 7
- 102100000368 F8 Human genes 0.000 claims 5
- 101700070229 F8 Proteins 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 230000001105 regulatory Effects 0.000 claims 5
- 102100006624 F9 Human genes 0.000 claims 4
- 108010054218 Factor VIII Proteins 0.000 claims 4
- 102000001690 Factor VIII Human genes 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102100001249 ALB Human genes 0.000 claims 3
- 101710027066 ALB Proteins 0.000 claims 3
- 102000003815 Interleukin-11 Human genes 0.000 claims 3
- 108090000177 Interleukin-11 Proteins 0.000 claims 3
- 229940074383 Interleukin-11 Drugs 0.000 claims 3
- 229920002459 Intron Polymers 0.000 claims 3
- 102000007584 Prealbumin Human genes 0.000 claims 3
- 108010071690 Prealbumin Proteins 0.000 claims 3
- 229940050528 albumin Drugs 0.000 claims 3
- 239000003114 blood coagulation factor Substances 0.000 claims 3
- 210000004027 cells Anatomy 0.000 claims 3
- 229940105778 coagulation factor VIII Drugs 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 229960004222 factor IX Drugs 0.000 claims 3
- 230000001402 polyadenylating Effects 0.000 claims 3
- 230000001225 therapeutic Effects 0.000 claims 3
- DTHNMHAUYICORS-KTKZVXAJSA-N 107444-51-9 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 2
- 102100017272 AFM Human genes 0.000 claims 2
- 101710024867 AFM Proteins 0.000 claims 2
- 102100017826 APOC3 Human genes 0.000 claims 2
- 101700049216 APOC3 Proteins 0.000 claims 2
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 2
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 2
- 101710010423 BN863_22000 Proteins 0.000 claims 2
- 229940009550 C1 esterase inhibitor Drugs 0.000 claims 2
- 101710026891 CES1 Proteins 0.000 claims 2
- 102100011049 CES1 Human genes 0.000 claims 2
- 102100006400 CSF2 Human genes 0.000 claims 2
- 102000000018 Chemokine CCL2 Human genes 0.000 claims 2
- 108010055292 Chemokine CCL2 Proteins 0.000 claims 2
- 108010062852 EC 2.7.1.3 Proteins 0.000 claims 2
- 102000003951 Erythropoietin Human genes 0.000 claims 2
- 108090000394 Erythropoietin Proteins 0.000 claims 2
- 102000003972 Fibroblast Growth Factor 7 Human genes 0.000 claims 2
- 108090000385 Fibroblast Growth Factor 7 Proteins 0.000 claims 2
- 102000018233 Fibroblast growth factor family Human genes 0.000 claims 2
- 108050007372 Fibroblast growth factor family Proteins 0.000 claims 2
- 101710042131 GCG Proteins 0.000 claims 2
- 102100003818 GCG Human genes 0.000 claims 2
- 101710007478 GJE1 Proteins 0.000 claims 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 108010051696 Growth Hormone Proteins 0.000 claims 2
- 102000018997 Growth Hormone Human genes 0.000 claims 2
- 101710007394 HAMP Proteins 0.000 claims 2
- 102100016195 HAMP Human genes 0.000 claims 2
- 102000013271 Hemopexin Human genes 0.000 claims 2
- 108010026027 Hemopexin Proteins 0.000 claims 2
- 208000009292 Hemophilia A Diseases 0.000 claims 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims 2
- 101700035985 IDS Proteins 0.000 claims 2
- 102100008356 IDS Human genes 0.000 claims 2
- 102100005003 IL5 Human genes 0.000 claims 2
- 102000003814 Interleukin-10 Human genes 0.000 claims 2
- 108090000174 Interleukin-10 Proteins 0.000 claims 2
- 229940076144 Interleukin-10 Drugs 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102000000646 Interleukin-3 Human genes 0.000 claims 2
- 108010002386 Interleukin-3 Proteins 0.000 claims 2
- 229940076264 Interleukin-3 Drugs 0.000 claims 2
- 102000004388 Interleukin-4 Human genes 0.000 claims 2
- 108090000978 Interleukin-4 Proteins 0.000 claims 2
- 229940028885 Interleukin-4 Drugs 0.000 claims 2
- 108010002616 Interleukin-5 Proteins 0.000 claims 2
- 229940100602 Interleukin-5 Drugs 0.000 claims 2
- 229940100601 Interleukin-6 Drugs 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 102000004890 Interleukin-8 Human genes 0.000 claims 2
- 108090001007 Interleukin-8 Proteins 0.000 claims 2
- 229940096397 Interleukin-8 Drugs 0.000 claims 2
- XKTZWUACRZHVAN-VADRZIEHSA-N Interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims 2
- 102000000585 Interleukin-9 Human genes 0.000 claims 2
- 108010002335 Interleukin-9 Proteins 0.000 claims 2
- 229940118526 Interleukin-9 Drugs 0.000 claims 2
- 102100006537 KHK Human genes 0.000 claims 2
- 108010001831 LDL receptors Proteins 0.000 claims 2
- 102100012475 LDLR Human genes 0.000 claims 2
- 102100011108 MASP2 Human genes 0.000 claims 2
- 101700062311 MASP2 Proteins 0.000 claims 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 claims 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102000009063 Nicotinamide N-Methyltransferase Human genes 0.000 claims 2
- 108010088865 Nicotinamide N-Methyltransferase Proteins 0.000 claims 2
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 2
- 102100012897 PGF Human genes 0.000 claims 2
- 101710014083 PGF Proteins 0.000 claims 2
- 102000017975 Protein C Human genes 0.000 claims 2
- 229960000856 Protein C Drugs 0.000 claims 2
- 102100018045 SERPINC1 Human genes 0.000 claims 2
- 101710039702 SERPINC1 Proteins 0.000 claims 2
- 102100008880 TFPI Human genes 0.000 claims 2
- 101710034269 TFPI Proteins 0.000 claims 2
- 108010000499 Thromboplastin Proteins 0.000 claims 2
- 102000002262 Thromboplastin Human genes 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 2
- 102100015249 VEGFA Human genes 0.000 claims 2
- 101700048951 VSPDV Proteins 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 229940024142 alpha 1-Antitrypsin Drugs 0.000 claims 2
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 2
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 230000002708 enhancing Effects 0.000 claims 2
- 229940105423 erythropoietin Drugs 0.000 claims 2
- 239000000122 growth hormone Substances 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 230000002132 lysosomal Effects 0.000 claims 2
- 108060005018 mobB Proteins 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 239000003001 serine protease inhibitor Substances 0.000 claims 2
- 210000001519 tissues Anatomy 0.000 claims 2
- 230000005030 transcription termination Effects 0.000 claims 2
- 102100006780 ADAMTS13 Human genes 0.000 claims 1
- 108091005662 ADAMTS13 Proteins 0.000 claims 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 1
- 102000016519 Coagulation factor VII Human genes 0.000 claims 1
- 102000005911 Complement C1 Inhibitor Protein Human genes 0.000 claims 1
- 108010005563 Complement C1 Inhibitor Protein Proteins 0.000 claims 1
- 108090000056 Complement Factor B Proteins 0.000 claims 1
- 102000003712 Complement Factor B Human genes 0.000 claims 1
- 101700024131 EXE4 Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exendin-4 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims 1
- 101700074227 F9 Proteins 0.000 claims 1
- 101710030892 FLT1 Proteins 0.000 claims 1
- 102100006565 FLT1 Human genes 0.000 claims 1
- 108010076282 Factor IX Proteins 0.000 claims 1
- 229960000301 Factor VIII Drugs 0.000 claims 1
- 108010054265 Factor VIIa Proteins 0.000 claims 1
- 229940012414 Factor VIIa Drugs 0.000 claims 1
- 108010014173 Factor X Proteins 0.000 claims 1
- 102000016970 Follistatin Human genes 0.000 claims 1
- 108010014612 Follistatin Proteins 0.000 claims 1
- 108060003199 Glucagon Proteins 0.000 claims 1
- 229960004666 Glucagon Drugs 0.000 claims 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N Glucagonum Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 1
- 206010061992 Haemophilia Diseases 0.000 claims 1
- 208000009429 Hemophilia B Diseases 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006822 Human Serum Albumin Proteins 0.000 claims 1
- 108010003381 Iduronidase Proteins 0.000 claims 1
- 102000004627 Iduronidase Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 102000003996 Interferon beta Human genes 0.000 claims 1
- 108090000467 Interferon beta Proteins 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 229960001388 Interferon-beta Drugs 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 108010023402 Interleukin 1 Receptor Antagonist Protein Proteins 0.000 claims 1
- 102000011294 Interleukin 1 Receptor Antagonist Protein Human genes 0.000 claims 1
- 102000000589 Interleukin-1 Human genes 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 229940117681 Interleukin-12 Drugs 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 108020004391 Introns Proteins 0.000 claims 1
- 102000017055 Lipoprotein lipase Human genes 0.000 claims 1
- 108010013563 Lipoprotein lipase Proteins 0.000 claims 1
- PXZWGQLGAKCNKD-DPNMSELWSA-N MolPort-023-276-326 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 claims 1
- 101800001388 Oxyntomodulin Proteins 0.000 claims 1
- 102400000319 Oxyntomodulin Human genes 0.000 claims 1
- 108091005771 Peptidases Proteins 0.000 claims 1
- 102000035443 Peptidases Human genes 0.000 claims 1
- 108010076181 Proinsulin Proteins 0.000 claims 1
- 102100019017 VWF Human genes 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 102000005840 alpha-Galactosidase Human genes 0.000 claims 1
- 108010030291 alpha-Galactosidase Proteins 0.000 claims 1
- 108090001123 antibodies Proteins 0.000 claims 1
- 102000004965 antibodies Human genes 0.000 claims 1
- 229940019336 antithrombotic Enzymes Drugs 0.000 claims 1
- -1 apoliprotein Proteins 0.000 claims 1
- 230000027455 binding Effects 0.000 claims 1
- 229940105772 coagulation factor VII Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960001519 exenatide Drugs 0.000 claims 1
- 201000007386 factor VII deficiency Diseases 0.000 claims 1
- 201000003542 factor VIII deficiency Diseases 0.000 claims 1
- 229940012426 factor X Drugs 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000000692 natriuretic peptide Substances 0.000 claims 1
- 235000019833 protease Nutrition 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000003612 virological Effects 0.000 claims 1
- 108010047303 von Willebrand Factor Proteins 0.000 claims 1
- 229960001134 von Willebrand factor Drugs 0.000 claims 1
Claims (31)
マウス微小ウイルス(MVM)イントロン;並びに/又は
転写終結シグナル;
を含む、請求項8に記載の核酸発現カセット。 at least one tissue-specific nucleic acid regulatory element operably linked to said promoter and said nucleic acid molecule as defined in any one of claims 1-6 ;
mouse minute virus (MVM) introns; and/or transcription termination signals;
9. The nucleic acid expression cassette of claim 8 , comprising:
前記転写終結シグナルがポリアデニル化シグナル、配列番号21に定められる合成ポリアデニル化シグナル又は配列番号23に定められるシミアンウイルス40(SV40)ポリアデニル化シグナルである; said transcription termination signal is a polyadenylation signal, a synthetic polyadenylation signal set forth in SEQ ID NO:21 or a simian virus 40 (SV40) polyadenylation signal set forth in SEQ ID NO:23;
請求項9に記載の核酸発現カセット。A nucleic acid expression cassette according to claim 9 .
凝固因子IX(FIX);
凝固第VIII因子(FVIII);又は
凝固第VII因子(FVII)若しくは因子FVIIa(FVIIa)の軽鎖若しくは重鎖;
をコードする、請求項11~14のいずれか一項に記載の核酸発現カセット。 the transgene is
clotting factor IX (FIX );
coagulation factor VIII (FVIII ); or the light or heavy chain of coagulation factor VII (FVII) or factor FVIIa (FVIIa);
The nucleic acid expression cassette according to any one of claims 11 to 14 , which encodes a
前記導入遺伝子がコドン最適化凝固因子FVIIIである、若しくは前記凝固第VIII因子がBドメインの欠損を有する;又は said transgene is a codon-optimized coagulation factor FVIII, or said coagulation factor VIII has a B domain deletion; or
前記FVII若しくはFVIIaの軽鎖が、FVII又はFVIIaの重鎖に1つ若しくは複数の切断可能なポリペプチド若しくはペプチドリンカーによって結合される; said FVII or FVIIa light chain is linked to the FVII or FVIIa heavy chain by one or more cleavable polypeptide or peptide linkers;
請求項15に記載の核酸発現カセット。16. A nucleic acid expression cassette according to claim 15.
前記FVIIIの前記Bドメインが配列番号15に定められるリンカーで置換される;又は said B domain of said FVIII is replaced with a linker set forth in SEQ ID NO: 15; or
前記FVII若しくはFVIIaの軽鎖が、FVII又はFVIIaの重鎖に1つ若しくは複数の切断可能なポリペプチド若しくはペプチドリンカーによって結合される; said FVII or FVIIa light chain is linked to the FVII or FVIIa heavy chain by one or more cleavable polypeptide or peptide linkers;
請求項16に記載の核酸発現カセット。17. A nucleic acid expression cassette according to claim 16.
前記導入遺伝子が、配列番号16に定められる核酸配列を有する凝固第VIII因子をコードする;又は said transgene encodes coagulation factor VIII having the nucleic acid sequence set forth in SEQ ID NO: 16; or
前記導入遺伝子が、配列番号34に定められるアミノ酸配列をコードする; said transgene encodes the amino acid sequence set forth in SEQ ID NO:34;
請求項11~17のいずれか一項に記載の核酸発現カセット。A nucleic acid expression cassette according to any one of claims 11-17.
、又はセルピンペプチダーゼ阻害剤、クレードC(アンチトロンビン)、メンバー1(SERPINC1)プロモーター若しくは最小限プロモーターから選択される肝臓特異的プロモーター、またはTTRmである、請求項8~23のいずれか一項に記載の核酸発現カセット。, or a liver-specific promoter selected from a serpin peptidase inhibitor, clade C (antithrombin), member 1 (SERPINC1) promoter or minimal promoter, or TTRm. of nucleic acid expression cassettes.
請求項8~24のいずれか一項に記載の前記核酸発現カセット又は請求項25又は26に記載の前記ベクターを前記肝臓細胞に導入すること;
前記導入遺伝子産物を前記肝臓細胞で発現させること;
を含む、方法。 An in vitro or ex vivo method for expressing a transgene product in liver cells, comprising:
introducing the nucleic acid expression cassette according to any one of claims 8 to 24 or the vector according to claim 25 or 26 into the liver cells;
expressing said transgene product in said liver cells;
A method, including
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18202888.6 | 2018-10-26 | ||
EP18202888 | 2018-10-26 | ||
PCT/EP2019/079351 WO2020084161A1 (en) | 2018-10-26 | 2019-10-28 | New tools for improving gene therapy and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022505876A JP2022505876A (en) | 2022-01-14 |
JPWO2020084161A5 true JPWO2020084161A5 (en) | 2022-11-08 |
Family
ID=64051422
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021522958A Pending JP2022505876A (en) | 2018-10-26 | 2019-10-28 | New tools and their use to improve gene therapy |
Country Status (5)
Country | Link |
---|---|
US (1) | US20210379203A1 (en) |
EP (1) | EP3870215A1 (en) |
JP (1) | JP2022505876A (en) |
CN (1) | CN113164560A (en) |
WO (1) | WO2020084161A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3094859A1 (en) * | 2020-10-01 | 2022-04-01 | Entos Pharmaceuticals Inc. | Proteolipid vesicles formulated with fusion associated small transmembrane proteins |
IL311240A (en) * | 2021-09-16 | 2024-05-01 | Generation Bio Co | Liver-specific expression cassettes, vectors and uses thereof for expressing therapeutic proteins |
CN116555266A (en) * | 2023-06-09 | 2023-08-08 | 呈诺再生医学科技(北京)有限公司 | Recombinant promoter and vector for liver specific expression and application of recombinant promoter and vector in liver related disease treatment |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1103373C (en) * | 1999-03-04 | 2003-03-19 | 上海贸基生物工程科技有限公司 | Chemical synthesis, expression and recombinant protein production for human serum albumin reformed gene |
EP2007885B1 (en) * | 2006-04-11 | 2010-07-21 | CSL Behring GmbH | Method of increasing the in vivo recovery of therapeutic polypeptides |
JP5797551B2 (en) | 2008-04-22 | 2015-10-21 | フエー・イー・ベー・フエー・ゼツト・ウエー | Liver-specific nucleic acid regulatory elements and methods and uses thereof |
GB0911870D0 (en) | 2009-07-08 | 2009-08-19 | Ucl Business Plc | Optimised coding sequence and promoter |
ES2475718T3 (en) * | 2009-07-10 | 2014-07-11 | Csl Limited | Method to increase the expression performance of vitamin K-dependent proteins |
US20120148557A1 (en) * | 2009-08-20 | 2012-06-14 | Ulrich Kronthaler | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
EP2717898B1 (en) * | 2011-06-10 | 2018-12-19 | Bioverativ Therapeutics Inc. | Pro-coagulant compounds and methods of use thereof |
AU2013336601B2 (en) * | 2012-10-26 | 2018-01-25 | Vrije Universiteit Brussel | Vector for liver-directed gene therapy of hemophilia and methods and use thereof |
US11072801B2 (en) | 2014-01-21 | 2021-07-27 | Vrije Universiteit Brussel | Muscle-specific nucleic acid regulatory elements and methods and use thereof |
JP6585721B2 (en) * | 2014-12-31 | 2019-10-02 | ディヴェロップメント センター フォー バイオテクノロジー | Humanized α-enolase specific antibodies and methods for their use in cancer therapy |
DK3270944T3 (en) | 2015-03-17 | 2020-01-27 | Univ Brussel Vrije | Optimized liver-specific expression systems for FVIII and FIX |
WO2017070167A1 (en) * | 2015-10-20 | 2017-04-27 | The University Of North Carolina At Chapel Hill | Methods and compositions for modified factor ix fusion proteins |
EP3393523B9 (en) | 2015-12-22 | 2023-10-04 | Vrije Universiteit Brussel | Endothelium-specific nucleic acid regulatory elements and methods and use thereof |
US10336812B2 (en) * | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
WO2018178067A1 (en) | 2017-03-27 | 2018-10-04 | Vrije Universiteit Brussel | Diaphragm-specific nucleic acid regulatory elements and methods and use thereof |
-
2019
- 2019-10-28 CN CN201980070614.8A patent/CN113164560A/en active Pending
- 2019-10-28 WO PCT/EP2019/079351 patent/WO2020084161A1/en unknown
- 2019-10-28 JP JP2021522958A patent/JP2022505876A/en active Pending
- 2019-10-28 EP EP19789569.1A patent/EP3870215A1/en not_active Withdrawn
- 2019-10-28 US US17/288,442 patent/US20210379203A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230293728A1 (en) | Liver-Specific Nucleic Acid Regulatory Elements and Methods and Use Thereof | |
RU2503688C2 (en) | Fused protein or peptide with increased half lifetime in vivo, which is maintained due to slow release in vivo, and method for increasing half lifetime in vivo using it | |
ES2332057T3 (en) | MUTEINS OF THE FIBROBLAST GROWTH FACTOR 21. | |
JP6649877B2 (en) | IgG4 Fc fragment containing mutated hinge region | |
EP1751184B1 (en) | Fgf-21 fusion proteins | |
CA2522590C (en) | Immunoglobulin chimeric monomer-dimer hybrids | |
KR101439817B1 (en) | Modified coagulation factor VIIa with extended half-life | |
US20050214253A1 (en) | Interferon-beta fusion proteins and uses | |
JP2007512001A (en) | EPO mimetic peptides and fusion proteins | |
JP2008522617A (en) | Fibroblast growth factor 21 mutein | |
JP2003530070A (en) | Expression and export of interferon-α protein as Fc fusion protein | |
JP6886920B2 (en) | New human serum albumin mutant | |
EP1711610A2 (en) | HETERODIMERIC FOLLICLE STIMULATING HORMONE-Fc (FSH-Fc) FUSION PROTEINS FOR THE TREATMENT OF INFERTILITY | |
EP1705248A1 (en) | Fusion proteins comprising an angiostatin moiety and their use in anti-tumour treatment | |
US20210403948A1 (en) | Liver-Specific Nucleic Acid Regulatory Elements and Methods and Use Thereof | |
US20210379203A1 (en) | New Tools for Improving Gene Therapy and Use Thereof | |
Zhang et al. | Development and biological activity of long-acting recombinant human interferon-α2b | |
JPWO2020084161A5 (en) | ||
EP3110434A1 (en) | Uti fusion proteins | |
US5958442A (en) | Oncostatin M for treating inflammation | |
Metzner et al. | Half‐Life Extension by Fusion to Recombinant Albumin | |
JP2008526875A (en) | New use | |
WO2024051787A1 (en) | Long-acting acylated insulin derivative and use thereof | |
Boswell et al. | α1-Antitrypsin: Molecules and medicine | |
CN1169733A (en) | Analogs of keratinocyte growth factor |